6.82
-0.155(-2.22%)
Currency In USD
Address
10865 Road to the Cure
San Diego, CA 92121
United States of America
Phone
310 358 3200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
160
First IPO Date
February 13, 2007
| Name | Title | Pay | Year Born |
| Dr. Linda Marbán Ph.D. | Co-Founder, President, Chief Executive Officer & Director | 389,862 | 1963 |
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board | 120,000 | 1956 |
| Ms. Karen G. Krasney Esq., J.D. | Executive Vice President, General Counsel & Secretary | 501,560 | 1953 |
| Mr. Anthony J. Bergmann M.B.A. | Chief Financial Officer & Corporate Treasurer | 539,230 | 1986 |
| Mr. Mark Awadalla | Chief Development Officer | 0 | N/A |
| Catherine Lee Kelleher | Consultant | 0 | N/A |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Science Officer | 0 | N/A |
| Mr. Minghao Sun Ph.D. | Senior Vice President of Research & Product Development | 0 | N/A |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
